(Photo: AbbVie)

AbbVie Announces Positive Phase 3 Data for Atogepant in Migraine Prevention

Originally posted on AbbVie.com

– Phase 3 ADVANCE trial evaluating atogepant meets primary endpoint of statistically significant reduction from baseline in mean monthly migraine days, compared to placebo, for all doses evaluated across a 12-week treatment period
– Trial also demonstrates statistically significant improvements in all six secondary endpoints in the 30 mg and 60 mg once-daily treatment arms
– Data from this trial and previous Phase 2/3 trial will be the basis for regulatory submissions in the U.S. and other countries
– These results support AbbVie’s commitment to providing multiple treatment options, including BOTOX® (onabotulinumtoxinA) for the prevention of chronic migraine and UBRELVY™ (ubrogepant), to treat migraine

AbbVie (NYSE: ABBV) today announced that the Phase 3 ADVANCE trial evaluating the investigational medicine atogepant, an orally administered calcitonin gene-related peptide (CGRP) receptor antagonist (gepant) met its primary endpoint of statistically significantly greater reduction in mean monthly migraine days, compared to placebo, for all doses across the 12-week treatment period. With these results, combined with the prior positive Phase 2/3 trial, AbbVie plans to move forward with regulatory submissions in the United States and other countries. Full data results will be presented at an upcoming medical congress and/or published in a peer-reviewed journal.

“Migraine attacks can be debilitating, but migraine is a treatable disease, and people living with it are not alone in their battle to control it,” said Thomas J. Hudson, M.D., senior vice president of R&D and chief scientific officer, AbbVie. “With the results from these trials, we aim to provide a safe and effective preventive treatment that offers patients and healthcare providers a simple, once daily oral treatment that works specifically by blocking CGRP receptors and preventing migraine.”

Latest News

Humana

Humana Reports Second Quarter 2020 Financial Results; Continues Proactive Relief Efforts Amid Pandemic

Originally posted on humana.com.  Ongoing actions to support its members, providers, employees, and communities during the COVID-19 pandemic, including the donation of an additional $150 million to the Humana Foundation to address social determinants of health in an effort to promote more healthy days and encourage greater health equity Reports…

BASF South East Asia joins ZDHC Foundation to Scale up Sustainability in the Leather, Textile, and Footwear Industry

Originally published on BASF.com BASF South East Asia now a “Contributor” in the Chemical Industry category of the ZDHC Foundation to help develop and implement chemical guidelines and solutions Haptex, BASF’s innovative polyurethane solution for synthetic leather, now certified ECO PASSPORT by OEKO-TEX® BASF South East Asia has joined the ZDHC…

AT&T Summer Camp

Originally published on ATT.com Welcome to AT&T Summer Camp For kids across the country, summer camp is something to look forward to all year long. It’s a time when they connect with friends, try new things, discover untapped talents and grow as individuals. This summer, we’re reimagining the summer camp…

Southern Company: Low-Income Natural Gas Customers to Receive $1 Million in Energy Assistance Support from Atlanta Gas Light

Originally published on southerncompany.com. Under a mechanism created by the Georgia Public Service Commission last year, Atlanta Gas Light is allocating $1 million for supplemental low-income energy assistance, which will be distributed to qualifying agencies that support customers who need help paying natural gas bills, repairing or replacing natural gas appliances…